Project Grant VSRNV000006

Federal Grant Award Summary Yale University received a $251,563 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 20, 2026, with a completion date of January 31, 2028. The grant funds a longitudinal cohort study assessing the immunogenicity of QDENGA (TAK-003), Takeda's dengue vaccine, in real-world conditions. The research deliverables include comprehensive immunological...

Cooperative Agreement Summary Boston Children's Hospital, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), received a cooperative agreement award of $1.67 million on September 25, 2025, to conduct a Phase 1 clinical study evaluating a novel messenger RNA (mRNA)-lipid nanoparticle (LNP)-based SARS-CoV-2 vaccine incorporating controlled biodistribution technology and interleukin-12...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $601,677 to the University of Massachusetts to conduct multi-scale characterization of antigen-polymerized immune complexes underlying thrombotic pathologies triggered by adenoviral-vectored vaccines. The research aims to study the emergence and progression of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but dangerous side effect of adenoviral...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

Federal Cooperative Agreement Summary Emory University received a $877,587 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 22, 2025, with completion targeted for July 31, 2030. The agreement funds a Phase 2B randomized open-label clinical trial to evaluate dengue immunity elicited by heterologous prime-boost vaccination combinations using TAK-003 and...

Federal Project Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $781,718 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2025 through May 31, 2030. The award supports the development of a novel T cell-based vaccine designed to prevent dengue virus (DENV) and Zika virus (ZIKV) infection while avoiding antibody-dependent enhancement...

Federal Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded $286,793 to the Benaroya Research Institute at Virginia Mason on September 24, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to conduct clinical trial planning activities for a study evaluating high-dose influenza vaccine safety and efficacy in individuals with Down syndrome under age 65. This R34 planning grant supports preparation for a randomized-controlled clinical trial...

Federal Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $194,400 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, through August 31, 2029. This research initiative addresses vaccine immunogenicity and immune response in allogeneic hematopoietic stem cell transplant (HCT) recipients, a population...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $522,524 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, with a completion date of June 30, 2030. This award supports research into the mechanism of inflammation in adenosine deaminase 2 (ADA2) deficiency (DADA2), a rare inborn error of immunity characterized by systemic inflammation, vascular involvement,...

This Project Grant award of $735,078 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Chicago to investigate the molecular mechanisms underlying innate immune memory and trained immunity in humans. The key objectives are to: 1) Characterize the epigenetic changes induced in human myeloid and lymphoid progenitor cells by trained immunity adjuvants, 2) Determine how these epigenetic...